Text Size

Levetiracetam Treatment of Tardive Dyskinesia

This study has been completed.
Sponsor:
Collaborator:
UCB, Inc.
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00291213
First received: February 10, 2006
Last updated: NA
Last verified: February 2006
History: No changes posted
  Purpose

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.


Condition Intervention Phase
Tardive Dyskinesia
 Drug: levetiracetam
Drug: placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Yale University:

Primary Outcome Measures:
  • AIMS total score

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: meet Glazer Morgenstern criteria for TD -

Exclusion Criteria: none

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00291213

Locations
United States, Connecticut
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
UCB, Inc.
Investigators
Principal Investigator: Scott W Woods, MD Yale School of Medicine
  More Information

No publications provided by Yale University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00291213     History of Changes
Other Study ID Numbers: YaleHIC26585
Study First Received: February 10, 2006
Last Updated: February 10, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Dyskinesias
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Etiracetam
Piracetam
 Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 17, 2013